Kellokumpu-Lehtinen, P., et al. “Cost-Effectiveness of Intensive Adjuvant Chemotherapy for High-Risk Breast Cancer: Is Tailored and Dose-Escalated Chemotherapy With Growth Factor Support (GFS) More Costly and Less Effective Than Marrow-Supported High-Dose Chemotherapy – Results from a Ra”. Acta Oncologica, vol. 46, no. 2, Jan. 2007, pp. 146-52, doi:10.1080/02841860600965012.